Development, implementation, and feasibility of site-specific hepatitis C virus treatment workflows for treating vulnerable, high-risk populations: protocol of the Erase Hep C study — a prospective single-arm intervention trial

BACKGROUND: Hepatitis C virus (HCV) is the leading indication for liver transplantation and liver-related mortality. The development of direct-acting antivirals (DAA) and a simplified treatment algorithm with a > 97% cure rate should make global elimination of HCV an achievable goal. Yet, vulnera...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Anmol, O’Neal, Lauren, Reinis, Kia, Chang, Patrick, Brown, Cristal, Stefanowicz, Michael, Kuang, Audrey, Agrawal, Deepak, Bhavnani, Darlene, Mercer, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165844/
https://www.ncbi.nlm.nih.gov/pubmed/37158965
http://dx.doi.org/10.1186/s40814-023-01311-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165844/
https://www.ncbi.nlm.nih.gov/pubmed/37158965
http://dx.doi.org/10.1186/s40814-023-01311-4

Ejemplares similares